Mesalazine

Overview

Mesalazine

File:Mesalazine structure.svg
Clinical data
Routes of administration	oral rectal
ATC code	A07EC02 (WHO)
Pharmacokinetic data
Bioavailability	orally: 20-30% absorbed rectally: 10-35%
Metabolism	Rapidly & extensively metabolised intestinal mucosal wall and the liver.
Elimination half-life	5 hours after initial dose. At steady state 7 hours
Identifiers
IUPAC name 5-amino-2-hydroxybenzoic acid
CAS Number	89-57-6
PubChem CID	4075
DrugBank	APRD01098
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C7H7NO3
Molar mass	153.135 g/mol

WikiDoc Resources for Mesalazine
Articles
Most recent articles on Mesalazine Most cited articles on Mesalazine Review articles on Mesalazine Articles on Mesalazine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mesalazine Images of Mesalazine Photos of Mesalazine Podcasts & MP3s on Mesalazine Videos on Mesalazine
Evidence Based Medicine
Cochrane Collaboration on Mesalazine Bandolier on Mesalazine TRIP on Mesalazine
Clinical Trials
Ongoing Trials on Mesalazine at Clinical Trials.gov Trial results on Mesalazine Clinical Trials on Mesalazine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mesalazine NICE Guidance on Mesalazine NHS PRODIGY Guidance FDA on Mesalazine CDC on Mesalazine
Books
Books on Mesalazine
News
Mesalazine in the news Be alerted to news on Mesalazine News trends on Mesalazine
Commentary
Blogs on Mesalazine
Definitions
Definitions of Mesalazine
Patient Resources / Community
Patient resources on Mesalazine Discussion groups on Mesalazine Patient Handouts on Mesalazine Directions to Hospitals Treating Mesalazine Risk calculators and risk factors for Mesalazine
Healthcare Provider Resources
Symptoms of Mesalazine Causes & Risk Factors for Mesalazine Diagnostic studies for Mesalazine Treatment of Mesalazine
Continuing Medical Education (CME)
CME Programs on Mesalazine
International
Mesalazine en Espanol Mesalazine en Francais
Business
Mesalazine in the Marketplace Patents on Mesalazine
Experimental / Informatics
List of terms related to Mesalazine

Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is a bowel-specific aminosalicylate drug that is metabolized in the gut and has its predominant actions there, thereby having fewer systemic side effects.

As a derivative of salicylic acid, 5-ASA is also an antioxidant that traps free radicals, which are potentially damaging by-products of metabolism.

5-ASA is considered the active moiety of sulfasalazine, which is metabolized to it.

Formulations

It is formulated for oral ingestion as tablets or granules, and for rectal administration as rectal suppository, suspension or enemas. It is sold under a variety of brand names (UK: Asacol, Ipocal, Pentasa & Salofalk. US: Canasa, Rowasa, Pentasa, Asacol and Lialda). The newest of these is Lialda, approved by the FDA in January 2007 for induction of remission in ulcerative colitis. Its main benefit is that it needs to be taken only once a day, which improves convenience and treatment compliance.

Dosing depends on the preparation used, in particular, slow-release tablets may have quite different drug delivery characteristics and are not interchangeable.

Preparations that lower stool pH (such as lactulose, a laxative) will affect the binding of Mesalazine in the bowel and will therefore reduce its efficacy.

Side effects

Commonly:

• Diarrhea
• Nausea
• Cramping

Uncommonly:

• Headache
• Exacerbation of the colitis
• Hypersensitivity reactions (including rash, urticaria, interstitial nephritis and lupus erythematosus-like syndrome)
• Hair Loss
• Interstitial nephritis

Rarely:

• Acute pancreatitis,
• Hepatitis
• Nephrotic syndrome
• Blood disorders (including agranulocytosis, aplastic anaemia, leukopenia, neutropenia, thrombocytopenia)

Mesalazine avoids the sulphonamide side effects of Sulfasalazine (which contains additional (sulfapyridine), but carries additional rare risks of:

• Allergic lung reactions
• Allergic myocarditis
• Methaemoglobinaemia

Monitoring

As a result of the small risks of kidney, liver and blood disorders, blood tests should be taken before and after starting treatment. Patients are advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment so that a full blood count can be urgently taken.

References

• British National Formulary 45 March 2003
• Edited by Sean C. Sweetman, ed. (November 30, 2004). Martindale: The complete drug reference (34th edition ed.). London: Pharmaceutical Press. ISBN 0-85369-550-4.CS1 maint: Extra text: editors list (link) CS1 maint: Extra text (link)

External links

• Optimal Dosing of 5-Aminosalicylic Acid: 5 Decades of Choosing Between Politicians
• "Novel formulation increases efficacy of mesalamine for treating ulcerative colitis" Reuters article on Lialda/Mezavant trial success.

Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents